| Sarah Nicole Mitchell, LPN | |
|
1250 S Manufacturers Row, Trenton, TN 38382-3632 | |
| (731) 855-7601 | |
| Not Available |
| Full Name | Sarah Nicole Mitchell |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 1250 S Manufacturers Row, Trenton, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629628300 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 0000090577 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Nicole Mitchell, LPN 1250 S Manufacturers Row, Trenton, TN 38382-3632 Ph: (731) 855-7601 | Sarah Nicole Mitchell, LPN 1250 S Manufacturers Row, Trenton, TN 38382-3632 Ph: (731) 855-7601 |
News Archive
Funded by volleyball tournaments, a new study released this week shows success in pinpointing individualized treatment for women with metastatic breast cancer, according to George Mason University researchers.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
Federal officials report that the Open Payments database, which seeks to make drug and medical device company payments to doctors and hospitals available to consumers, is missing $1.1 billion in payments made between August and December 2013.
Orthovita, Inc., an orthobiologics and biosurgery company, notes that the August 10, 2010 online edition of The Lancet includes the largest peer-reviewed study to date demonstrating the efficacy of vertebroplasty in the treatment of acute vertebral compression fractures compared to conservative treatment.
April 29 marks a pivotal moment in cancer research when the world's brightest minds come together to discuss how to translate the success of CAR T-cell therapies for blood cancers into successful cell and gene therapies for the most complex and deadly solid tumor cancers.
› Verified 6 days ago